Samy Suissa1, Sophie Dell'Aniello2, Pierre Ernst2. 1. Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, and the Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada. Electronic address: samy.suissa@mcgill.ca. 2. Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, and the Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Abstract
BACKGROUND: Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are recommended as initial maintenance treatments for COPD, with their combination (LABA-LAMA) advocated as the disease progresses. Randomized trials comparing the effectiveness of this combination with the alternative combination of LABA with inhaled corticosteroid (LABA-ICS) have reported conflicting data, while there are no real-world comparative effectiveness and safety studies of these regimens in clinical practice settings. METHODS: We identified a cohort of patients with COPD during 2002-2015, age 55 years or older, from the United Kingdom's Clinical Practice Research Datalink. Patients initiating LABA-LAMA on the same day (no ICS) were matched on time-conditional high-dimensional propensity scores with patients initiating LABA-ICS on the same day (no LAMA), and monitored for 1 year for the occurrence of a moderate or severe COPD exacerbation and severe pneumonia. RESULTS: The cohort included 1,977 initiators of LABA-LAMA matched with 1,977 initiators of LABA-ICS. The hazard ratio (HR) of moderate or severe COPD exacerbation associated with LABA-LAMA initiation, relative to LABA-ICS initiation, was 1.04 (95% CI, 0.90-1.20), while for a severe exacerbation it was 0.94 (95% CI, 0.65-1.36). The incidence of severe pneumonia requiring hospitalization was lower with LABA-LAMA initiation (HR, 0.66; 95% CI, 0.41-1.05), particularly in the on-treatment analysis (HR, 0.66; 95% CI, 0.50-0.87). CONCLUSIONS: In a real-world clinical practice setting of COPD treatment, combined LABA-LAMA inhalers appear to be as effective as combined LABA-ICS inhalers in preventing COPD exacerbations. However, a LABA-LAMA combination may be preferred because it is associated with fewer severe pneumonias.
BACKGROUND: Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are recommended as initial maintenance treatments for COPD, with their combination (LABA-LAMA) advocated as the disease progresses. Randomized trials comparing the effectiveness of this combination with the alternative combination of LABA with inhaled corticosteroid (LABA-ICS) have reported conflicting data, while there are no real-world comparative effectiveness and safety studies of these regimens in clinical practice settings. METHODS: We identified a cohort of patients with COPD during 2002-2015, age 55 years or older, from the United Kingdom's Clinical Practice Research Datalink. Patients initiating LABA-LAMA on the same day (no ICS) were matched on time-conditional high-dimensional propensity scores with patients initiating LABA-ICS on the same day (no LAMA), and monitored for 1 year for the occurrence of a moderate or severe COPD exacerbation and severe pneumonia. RESULTS: The cohort included 1,977 initiators of LABA-LAMA matched with 1,977 initiators of LABA-ICS. The hazard ratio (HR) of moderate or severe COPD exacerbation associated with LABA-LAMA initiation, relative to LABA-ICS initiation, was 1.04 (95% CI, 0.90-1.20), while for a severe exacerbation it was 0.94 (95% CI, 0.65-1.36). The incidence of severe pneumonia requiring hospitalization was lower with LABA-LAMA initiation (HR, 0.66; 95% CI, 0.41-1.05), particularly in the on-treatment analysis (HR, 0.66; 95% CI, 0.50-0.87). CONCLUSIONS: In a real-world clinical practice setting of COPD treatment, combined LABA-LAMA inhalers appear to be as effective as combined LABA-ICS inhalers in preventing COPD exacerbations. However, a LABA-LAMA combination may be preferred because it is associated with fewer severe pneumonias.
Authors: Thomas Keller; Laura J Spece; Lucas M Donovan; Edmunds Udris; Scott S Coggeshall; Matthew Griffith; Alexander D Bryant; Richard Casaburi; J Allen Cooper; Gerard J Criner; Philip T Diaz; Anne L Fuhlbrigge; Steven E Gay; Richard E Kanner; Fernando J Martinez; Ralph J Panos; David Shade; Alice Sternberg; Thomas Stibolt; James K Stoller; James Tonascia; Robert Wise; Roger D Yusen; David H Au; Laura C Feemster Journal: Chest Date: 2020-04-09 Impact factor: 9.410
Authors: Jennifer K Quint; Jukka Montonen; Daina B Esposito; Xintong He; Leslie Koerner; Laura Wallace; Alberto de la Hoz; Marc Miravitlles Journal: Adv Ther Date: 2021-03-15 Impact factor: 3.845
Authors: Gema Requena; Daniel Dedman; Jennifer K Quint; Rebecca E Ghosh; Rachael Williams; Jeanne M Pimenta Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-03-10
Authors: Timothy H Harries; Victoria Rowland; Christopher J Corrigan; Iain J Marshall; Lucy McDonnell; Vibhore Prasad; Peter Schofield; David Armstrong; Patrick White Journal: Respir Res Date: 2020-01-03
Authors: José William Zucchi; Estefânia Aparecida Thomé Franco; Thomas Schreck; Maria Helena Castro E Silva; Sandro Rogerio Dos Santos Migliorini; Thaís Garcia; Gustavo Augusto Ferreira Mota; Bruna Evelyn Bueno de Morais; Luiz Henrique Soares Machado; Ana Natália Ribeiro Batista; Sergio Alberto Rupp de Paiva; Irma de Godoy; Suzana Erico Tanni Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-11-06
Authors: Jaco Voorham; Simonetta Baldi; Luigi Santoro; Marjan Kerkhof; Marco Contoli; Leonardo M Fabbri; Huib A M Kerstjens; Jose Luis López-Campos; Nicolas Roche; Dave Singh; Claus F Vogelmeier; David B Price Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-10-29